Clovis Oncology Inc

Most Recent

  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

    By Daniel Collins
  • uploads///cancer _
    Company & Industry Overviews

    Tesaro Stock Up over 16% on Rumors of Acquisition by Roche

    Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.

    By Sarah Collins
  • uploads///Graph Part
    Company & Industry Overviews

    XBI’s Moving Averages: The Massive Plummet Last Week

    XBI’s moving average took a hit in the week ended September 25, and most of its stocks were trading below all the moving averages. Compared to the previous week, the fall was massive.

    By Peter Neil
  • uploads///bacteria _
    Company & Industry Overviews

    Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today

    Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10.

    By Daniel Collins
  • uploads///medic _
    Company & Industry Overviews

    Why Clovis Oncology Stock Rose 48% in November

    On December 3, Clovis Oncology stock closed at $19.08, which represents ~10.87% growth from its close of $17.21 on November 30.

    By Daniel Collins
  • uploads///CLVS
    Company & Industry Overviews

    Gauging Analysts’ Views on Clovis Stock

    In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    How Clovis Oncology Is Positioned in November

    Clovis Oncology generated total revenue of $22.76 million in the third quarter compared to $16.81 million in the comparable period of 2017.

    By Kenneth Smith
  • uploads///dna _
    Earnings Report

    Portola Pharmaceuticals Stock Rose after Its Q3 2018 Results

    On November 8, after Portola Pharmaceuticals released its third-quarter financial results, the stock price rose 21.41%.

    By Daniel Collins
  • uploads///microscope _
    Healthcare

    Here’s What’s Driving Investor Interest in Immunomedics

    Clinical stage biopharmaceutical company Immunomedics (IMMU) is currently focused on advancing several research programs.

    By Margaret Patrick
  • uploads///laboratory _
    Company & Industry Overviews

    Exact Sciences: Why the Stock Price Is Soaring

    On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.

    By Daniel Collins
  • uploads///TSRO
    Company & Industry Overviews

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

    By Kenneth Smith
  • uploads///thermometer _
    Company & Industry Overviews

    Analyst Recommendations for Exelixis in August

    In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, a 66% YoY growth.

    By Daniel Collins
  • uploads///molecule _
    Earnings Report

    What to Expect from Clovis Oncology’s Q2 2018 Earnings

    Biopharmaceutical company Clovis Oncology (CLVS) is expected to report its second-quarter earnings on August 1.

    By Kenneth Smith
  • uploads///CLVS
    Company & Industry Overviews

    A Review of Clovis Oncology’s Financial Performance

    In the first quarter, Clovis Oncology’s (CLVS) product revenue rose YoY (year-over-year) to $18.5 million from $7 million.

    By Kenneth Smith
  • uploads///CLVS pipeline
    Company & Industry Overviews

    A Look at Clovis Oncology’s Clinical Programs

    The FDA’s approval of Clovis Oncology’s (CLVS) Rubraca for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in April was the second and much broader indication the drug has been approved for.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    How Lynparza Performed in 1Q18

    On July 27, Merck (MRK) and AstraZeneca (AZN) announced a strategic global collaboration for co-developing and co-commercializing the latter’s poly ADP ribose polymerase (or PARP) inhibitor, Lynparza.

    By Margaret Patrick
  • uploads///Lynparza
    Company & Industry Overviews

    AstraZeneca’s Lynparza Witnessed High Growth in 2017

    In 4Q17, AstraZeneca’s (AZN) Lynparza reported revenues of $100.0 million, which reflected ~61.0% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Gilead Sciences on the Street: Analyst Recommendations in October

    Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy.”

    By Daniel Collins
  • uploads///Rising consumer sentiment helping the market rally in
    Company & Industry Overviews

    Is Rising Consumer Sentiment Helping the Market Rally in 2017?

    The S&P 500 Index (SPX-INDEX) has posted a rise of ~5% since the beginning of 2017, with banks and energy stocks leading the rally as of March 29, 2017.

    By Mary Sadler
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Small-Caps Reduce Negative Returns in December

    The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Immunogen Topped the Small-Cap Stocks with High Volumes

    Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Pacira’s Strong 3Q15 Results Helped the Pharma Subgroup

    Pacira Pharmaceuticals (PCRX) rose 19.5% and closed at $49.12. Pacira had a weight of 0.25% in IBB’s portfolio. It was one of the top performers on October 27.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Dyax Traded above Its 100-Day Moving Average

    Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Performance of XBI and IBB with Respective Benchmark Indexes

    The SPDR S&P Biotech ETF (XBI) fell 4.53%. It tracks the S&P Biotechnology Select Industry Index as its benchmark index, which fell 4.32% for the week ended September 4.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Pharmaceutical Stocks Affect the iShares NASDAQ Biotechnology ETF

    Out of 62 stocks held within the pharmaceutical subgroup of the iShares NASDAQ Biotechnology ETF (IBB), 49 stocks fell during the week ending August 7, 2015.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Moving Average Analysis of the Pharmaceutical Subgroup

    For the week ending July 31, the stocks that moved into the 100-day moving average zone include Akorn, Clovis Oncology, Endo International, and Grifols.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.